BWMX enters the final days of May with a clean and unusual setup: options traders are positioning bullishly at levels near a full-year extreme, even as short interest has more than doubled in a month yet remains too small to tell a meaningful story on its own.
The options signal is the standout this week. The put/call ratio has collapsed to 0.20 — well below its 20-day average of 0.58 and roughly one standard deviation beneath it. That puts the ratio close to its 52-week low of 0.02, reflecting near-total dominance of call activity over puts. The shift is stark: as recently as late April and early May, the PCR ran above 1.0 for weeks, touching a 52-week high of 1.44 on April 24. In less than three weeks, options traders have flipped from maximum defensiveness to something close to maximum optimism. Calls are crowding out protection.
Short interest tells a less urgent story, but is worth flagging. Short interest has roughly doubled since early May — up 148% over the past month to about 155,000 shares — and is currently around 1.1% of the free float. That is a genuine build, but it remains modest in absolute terms. Borrow conditions are entirely relaxed: the cost to borrow is under 0.6% annualised, and availability is running at 833% of short interest — meaning there are more than eight shares available to borrow for every one currently lent out. Earlier this month there was a brief spike to 19% on May 12, but that was resolved within days. The lending market is not stressed, and the short build is not being amplified by a tight borrow environment.
Analyst coverage is thin and concentrated. The only recent activity comes from Small Cap Consumer Research, which has repeatedly reiterated a Buy with a $30 price target — implying roughly 73% upside from the current $17.31 close. Freedom Broker raised its target to $31 in March. Both ratings are Buy, and both targets sit well above the current price. Coverage from bellwether firms is absent; the institutional holder list is dominated by Campalier S.A. de C.V., the founding shareholder, at over 54% of shares. The float is narrow as a result, which helps explain how the short interest can be modest in absolute share count while still registering as a percentage move. Valuation looks undemanding — the EV/EBITDA multiple is running near 3.9x, and the PE around 6.6x, both at levels that reflect the market's caution about execution and FX exposure rather than any premium for growth. The EV/EBIT factor score ranks in the 92nd percentile, a signal that the stock screens as cheap relative to earnings power across the broader universe.
On the fundamental debate, bulls point to the Tupperware LatAm acquisition as a top-line catalyst, alongside signs of stabilisation in the Betterware division — distributor and associate counts grew more than 5% last quarter. Bears counter that the acquisition brings integration risk and added debt, the company's products are priced in USD while revenues are exposed to the Mexican peso, and competition from better-capitalised rivals is growing. The ORTEX stock score has retreated from a six-month high of 95 in late April to 81 now, with quality and momentum both compressing. EPS surprise ranks in the 99th percentile, but forward EPS growth sits in just the 22nd percentile — a company beating low expectations rather than consistently raising them.
The CEO, Andres Chevallier, bought 10,000 shares at $16.81 on April 28, a transaction worth $168,000. The purchase came days after earnings on April 23, when the stock fell 6.3% on the day and 6.9% over the following week. That insider buy is the most recent purchase on record and adds a note of internal conviction to a setup where the stock has since recovered and pushed 3.8% higher over the past week.
The next scheduled earnings date is July 23. Between now and then, the key variables to watch are whether the sharp PCR reversal persists or reverts toward its prior range, how the short interest build progresses given the loose borrow conditions, and any updates on Tupperware LatAm integration progress that could test the gap between the $17 market price and the $30–31 analyst targets.
See the live data behind this article on ORTEX.
Open BWMX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
